Cargando…
Drug–Drug Interactions Involving Dexamethasone in Clinical Practice: Myth or Reality?
Concomitant administration of multiple drugs frequently causes severe pharmacokinetic or pharmacodynamic drug–drug interactions (DDIs) resulting in the possibility of enhanced toxicity and/or treatment failure. The activity of cytochrome P450 (CYP) 3A4 and P-glycoprotein (P-gp), a drug efflux pump s...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10672071/ https://www.ncbi.nlm.nih.gov/pubmed/38002732 http://dx.doi.org/10.3390/jcm12227120 |
_version_ | 1785149487963963392 |
---|---|
author | Bourdin, Venceslas Bigot, William Vanjak, Anthony Burlacu, Ruxandra Lopes, Amanda Champion, Karine Depond, Audrey Amador-Borrero, Blanca Sene, Damien Comarmond, Chloe Mouly, Stéphane |
author_facet | Bourdin, Venceslas Bigot, William Vanjak, Anthony Burlacu, Ruxandra Lopes, Amanda Champion, Karine Depond, Audrey Amador-Borrero, Blanca Sene, Damien Comarmond, Chloe Mouly, Stéphane |
author_sort | Bourdin, Venceslas |
collection | PubMed |
description | Concomitant administration of multiple drugs frequently causes severe pharmacokinetic or pharmacodynamic drug–drug interactions (DDIs) resulting in the possibility of enhanced toxicity and/or treatment failure. The activity of cytochrome P450 (CYP) 3A4 and P-glycoprotein (P-gp), a drug efflux pump sharing localization and substrate affinities with CYP3A4, is a critical determinant of drug clearance, interindividual variability in drug disposition and clinical efficacy, and appears to be involved in the mechanism of numerous clinically relevant DDIs, including those involving dexamethasone. The recent increase in the use of high doses of dexamethasone during the COVID-19 pandemic have emphasized the need for better knowledge of the clinical significance of drug–drug interactions involving dexamethasone in the clinical setting. We therefore aimed to review the already published evidence for various DDIs involving dexamethasone in vitro in cell culture systems and in vivo in animal models and humans. |
format | Online Article Text |
id | pubmed-10672071 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-106720712023-11-15 Drug–Drug Interactions Involving Dexamethasone in Clinical Practice: Myth or Reality? Bourdin, Venceslas Bigot, William Vanjak, Anthony Burlacu, Ruxandra Lopes, Amanda Champion, Karine Depond, Audrey Amador-Borrero, Blanca Sene, Damien Comarmond, Chloe Mouly, Stéphane J Clin Med Review Concomitant administration of multiple drugs frequently causes severe pharmacokinetic or pharmacodynamic drug–drug interactions (DDIs) resulting in the possibility of enhanced toxicity and/or treatment failure. The activity of cytochrome P450 (CYP) 3A4 and P-glycoprotein (P-gp), a drug efflux pump sharing localization and substrate affinities with CYP3A4, is a critical determinant of drug clearance, interindividual variability in drug disposition and clinical efficacy, and appears to be involved in the mechanism of numerous clinically relevant DDIs, including those involving dexamethasone. The recent increase in the use of high doses of dexamethasone during the COVID-19 pandemic have emphasized the need for better knowledge of the clinical significance of drug–drug interactions involving dexamethasone in the clinical setting. We therefore aimed to review the already published evidence for various DDIs involving dexamethasone in vitro in cell culture systems and in vivo in animal models and humans. MDPI 2023-11-15 /pmc/articles/PMC10672071/ /pubmed/38002732 http://dx.doi.org/10.3390/jcm12227120 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Bourdin, Venceslas Bigot, William Vanjak, Anthony Burlacu, Ruxandra Lopes, Amanda Champion, Karine Depond, Audrey Amador-Borrero, Blanca Sene, Damien Comarmond, Chloe Mouly, Stéphane Drug–Drug Interactions Involving Dexamethasone in Clinical Practice: Myth or Reality? |
title | Drug–Drug Interactions Involving Dexamethasone in Clinical Practice: Myth or Reality? |
title_full | Drug–Drug Interactions Involving Dexamethasone in Clinical Practice: Myth or Reality? |
title_fullStr | Drug–Drug Interactions Involving Dexamethasone in Clinical Practice: Myth or Reality? |
title_full_unstemmed | Drug–Drug Interactions Involving Dexamethasone in Clinical Practice: Myth or Reality? |
title_short | Drug–Drug Interactions Involving Dexamethasone in Clinical Practice: Myth or Reality? |
title_sort | drug–drug interactions involving dexamethasone in clinical practice: myth or reality? |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10672071/ https://www.ncbi.nlm.nih.gov/pubmed/38002732 http://dx.doi.org/10.3390/jcm12227120 |
work_keys_str_mv | AT bourdinvenceslas drugdruginteractionsinvolvingdexamethasoneinclinicalpracticemythorreality AT bigotwilliam drugdruginteractionsinvolvingdexamethasoneinclinicalpracticemythorreality AT vanjakanthony drugdruginteractionsinvolvingdexamethasoneinclinicalpracticemythorreality AT burlacuruxandra drugdruginteractionsinvolvingdexamethasoneinclinicalpracticemythorreality AT lopesamanda drugdruginteractionsinvolvingdexamethasoneinclinicalpracticemythorreality AT championkarine drugdruginteractionsinvolvingdexamethasoneinclinicalpracticemythorreality AT depondaudrey drugdruginteractionsinvolvingdexamethasoneinclinicalpracticemythorreality AT amadorborreroblanca drugdruginteractionsinvolvingdexamethasoneinclinicalpracticemythorreality AT senedamien drugdruginteractionsinvolvingdexamethasoneinclinicalpracticemythorreality AT comarmondchloe drugdruginteractionsinvolvingdexamethasoneinclinicalpracticemythorreality AT moulystephane drugdruginteractionsinvolvingdexamethasoneinclinicalpracticemythorreality |